Known targets — ChEMBL curated mechanism
PIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Pictilisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 16/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 15/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 14/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 12/20 | 1.00 |
| ▸ | PIK3R2 known ✓ | O00459 | 1/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 1.00 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 1/20 | 1.00 |
| ▸ | PIK3C2A | O00443 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | PIK3C2B | O00750 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pictilisib SCHEMBL14859338 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL29375636 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL29387739 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| SCHEMBL190513 | 0.98 | PIK3CA (0.95) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL29370279 | 0.98 | ABCC4 (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL29915227 | 0.98 | ABCC4 (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL3045698 | 0.95 | ABCC4 (0.92) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| Pictilisib SCHEMBL31237882 | 0.94 | PIK3CA (0.89) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| SCHEMBL31205 | 0.94 | PIK3CA (0.88) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A | |
| SCHEMBL190211 | 0.93 | PIK3CA (0.87) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6131 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636376-B2 | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors | IN3BIO LTD. (BM) | 2026-05-26 | — | — | US | claimed |
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| US-20260102500-A1 | PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING | SMARTDYELIVERY GMBH (DE) | 2026-04-16 | — | — | US | claimed |
| US-20260103461-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | OLEMA PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | claimed |
| US-20260097038-A1 | COMPOSITIONS OF ADAGRASIB AND mTOR INHIBITORS AND METHODS OF TREATMENT THEREWITH | Mirati Therapeutics, Inc. (US) | 2026-04-09 | — | — | US | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260083752-A1 | PHARMACEUTICAL METHODS, COMPOSITIONS AND COMBINATIONS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-03-26 | — | — | US | claimed |
| EP-4709382-A1 | METHODS OF TREATING SQUAMOUS CELL CARCINOMA WITH A FARNESYLTRANSFERASE INHIBITOR AND A PI3K INHIBITOR | Kura Oncology, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-2024372-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVE USEFUL AS PI3K INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-06-23 | — | — | EP | claimed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| US-20090098135-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. | 2009-04-16 | — | — | US | claimed |
| EP-2041139-A2 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-01 | — | — | EP | claimed |
| WO-2009036082-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-03-19 | — | — | WO | claimed |
| EP-2024372-A2 | THIENO [3,2-D] PYRIMIDINE DERIVATIVE USEFUL AS PI3K INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-18 | — | — | EP | claimed |
| US-20080076768-A1 | Pharmaceutical compounds | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | claimed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | claimed |
| WO-2007129161-A2 | THIENO [3, 2-D] PYRIMIDINE DERIVATIVE USEFUL AS PI3K INHIBITOR | F. HOFFMANN-LA ROCHE AG (US) | 2007-11-15 | — | — | WO | claimed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | claimed |